Treatment of COVID-19 by stage: any space left for mesenchymal stem cell therapy

Gaia Spinetti, Elisa Avolio, Paolo Madeddu

Research output: Contribution to journalReview article (Academic Journal)peer-review

Abstract

In many countries, COVID-19 now accounts for more deaths per year than car accidents and even the deadliest wars. Combating the viral pandemics requires a coordinated effort to develop therapeutic protocols adaptable to the disease severity. In this review article, we summarize a graded approach aiming to shield cells from SARS-CoV-2 entry and infection, inhibit excess inflammation and evasion of the immune response, and ultimately prevent systemic organ failure. Moreover, we focus on mesenchymal stem cell therapy, which has shown safety and efficacy as a treatment of inflammatory and immune diseases. The cell therapy approach is now repurposed in patients with severe COVID-19. Numerous trials of mesenchymal stem cell therapy are ongoing, especially in China and the USA. Leader companies in cell therapy have also started controlled trials utilizing their quality assessed cell products. Results are too premature to reach definitive conclusions.
Original languageEnglish
Pages (from-to)477-494
Number of pages18
JournalRegenerative Medicine
Volume16
Issue number5
Early online date14 May 2021
DOIs
Publication statusPublished - May 2021

Bibliographical note

Funding Information:
No writing assistance was utilized in the production of this manuscript. This paper was supported by a grant from the British Heart Foundation to P Madeddu and E Avolio Reference PG/20/10285 ?Targeting the SARS-CoV-2 S-protein binding to the ACE2 receptor to preserve human cardiac pericytes function in COVID-19?. Moreover, funding/financial support was obtained from the Italian Ministry of Health, Ricerca Corrente to G Spinetti at the IRCCS MultiMedica. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Funding Information:
This paper was supported by a grant from the British Heart Foundation to P Madeddu and E Avolio Reference PG/20/10285 ‘Targeting the SARS-CoV-2 S-protein binding to the ACE2 receptor to preserve human cardiac pericytes function in COVID-19’. Moreover, funding/financial support was obtained from the Italian Ministry of Health, Ricerca Corrente to G Spinetti at the IRCCS MultiMedica. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript.

Publisher Copyright:
© 2021 Future Medicine Ltd.. All rights reserved.

Structured keywords

  • Covid19

Keywords

  • acute respiratory distress syndrome
  • coronavirus
  • cytokine storm
  • epithelial cells
  • infection
  • mesenchymal stem cells
  • vascular cells

Fingerprint

Dive into the research topics of 'Treatment of COVID-19 by stage: any space left for mesenchymal stem cell therapy'. Together they form a unique fingerprint.

Cite this